On December 7, 2024, Edwards Lifesciences EW Corporation (NYSE: EW, $76.90, Market Capitalization: $46.6 billion) in its annual investor call announced its plans to spin-off its Critical Care unit ...
Edwards Lifesciences can say two things about its Pascal Precision Valve Repair System. The first is that the technology has FDA approval and the second is that in a study, the device showed its ...
“In the third quarter, we took important actions to sharpen our focus on structural heart by divesting Critical Care and investing in platforms to impact more patients and position Edwards for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results